Tag: AKT

Cell and Gene Therapy, Industry

AZ first to AKT finish line, but FDA clears narrow label

November 17, 2023

Via: Pharmaphorum

Capivasertib has been approved as Truqap for use in combination with AZ’s oestrogen receptor antagonist Faslodex (fulvestrant) for adults with hormone receptor (HR)-positive and HER2-negative locally advanced or metastatic breast cancer, but only if they also have PIK3CA, AKT1, or […]